Testing the role of P-glycoprotein expression in clinical trials: Applying pharmacological principles and best methods for detection together with good clinical trials methodology

International Journal of Clinical Pharmacology and Therapeutics

Volumn 36, Issue 1, 1998, Pages 29-40

  Ferry, D R ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Chemotherapy; GF120918; MDR; Pgp

Indexed keywords

ADENOSINE TRIPHOSPHATASE; DOXORUBICIN; FLUORESCENT DYE; GLYCOPROTEIN P; PACLITAXEL; RHODAMINE; VINCA ALKALOID;

BREAST CANCER; CANCER; CANCER SURVIVAL; CELL SURFACE; COLON CANCER; CONFERENCE PAPER; GOOD CLINICAL PRACTICE; HUMAN; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; METHODOLOGY; MULTIDRUG RESISTANCE; OVARY CANCER; PREDICTION; PROTEIN DETERMINATION; PROTEIN EXPRESSION; RELAPSE; RNA PROBE; TREATMENT FAILURE;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; HUMANS; NEOPLASMS; NEOPLASMS, EXPERIMENTAL; P-GLYCOPROTEIN; RESEARCH DESIGN;

EID: 0031972543     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (96)

1. Abe Y, Nakamura M, Ota E, Ozeki Y, Tamai S, Inoue H, Ueyama Y, Ogata T, Tamaoki N 1994 Expression of the multidrug resistance gene (MDR1) in nonsmall cell lung cancer. Jpn J Cancer Res 85: 536-541
2. Ackland SP, Ratain MJ, Vogelzang NJ, Choi KE, Ruane M, Sinkule JA 1989 Pharmacokinetics and pharmacodynamics of long-term continuous infusion doxorubicin. Clin Pharmacol Ther 45: 340-347
3. Aisenberg AC 1995 Coherent view of Non-Hodgkin's lymphoma J. Clin Oncol 13: 2656-2657
4. Arao S, Suwa H, Mandai M, Tashiro H, Miyazaki K, Okamura H, Nomura H, Hiai H, Fukumoto M 1994 Expression of multidrug resistance gene and localization of P-glycoprotein in human primary ovarian cancer. Cancer Res 54: 1355-1359
5. Arceci RJ, Stieglitz K, Bras J, Schinkel A, Baas F, Croop J 1993 Monoclonal antibody to an external epitope of the human mdr1 P-glycoprotein. Cancer Res 53: 310-317
6. Arredondo M, Guimaraes M, Tsangaris T, Slocum H, Rustum YM 1992 P-glycoprotein content of aneuploid and diploid populations of human breast carcinoma. Proc Annu Meet Am Soc Clin Oncol 11: A212
7. Awada A, Pagani O, Piccart M, Leyvraz S, Cerny T, Sessa C, Cavalli F, Coquoz D, Marinus W, Gerard B 1993 Phase I clinical and pharmacokinetic trials of S9788 alone and in combination with adriamycin (ADM). Proc Annu Meet Am Ass Cancer Res 34: A1274
8. Bak M, Hanna E, Csokay B, Bodrogi I, Olah E 1995 Multidrug resistance of testicular cancers. Detection of P-glycoprotein and MDR1 gene expression and their clinical connection. Orv Hetil 136: 19-25
9. Bartlett NL, Lum BL, Fisher GA, Brpphy NA, Ehsan MN, Halsey J, Sikic BI 1994 Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance. J Clin Oncol 12: 835-842
10. Becker I, Becker KF, Meyermann R, Hollt V 1991 The multidrug resistance gene mdr1 is expressed in human glial tumors. Acta Neuropathol (Berl) 82: 516-519
11. Berg S, Tolcher A, O'Shaughnessy JA, Denicoff AM, Noone M, Ognibene FP, Cowan KH, Balis FM, Barnes C 1995 Effect of R-verapamil on the pharmacokinetics of paclitaxel in women with breast cancer. J Clin Oncol 13: 2039-2042
12. Bittl A, Nap M, Jager W, Lathan B, Lang N 1991 Immunocytochemical determination of P-170 expression in malignant effusions of patients with breast or ovarian cancer using the three monoclonal antibodies JSB-1, C219, and 265/F4. J Cancer Res Clin Oncol 117: S91
13. Bittl A, Nap M, Jager W, Lathan B, Lang N 1993 Immunohistochemical detection of P-glycoprotein in normal and malignant tissues: a comparative study of three monoclonal antibodies, JSB-1, C219, and 265/F4, against different epitopes using frozen and paraffin tissue sections. Tumor Biol 14: 155-166
14. Botti G, Chiappetta G, D'Aiuto G, de AE, De MA, Montella M, Picone A, Cascione F 1993 PCNA/cyclin and P-glycoprotein as prognostic factors in locally advanced breast cancer. An immunohistochemical, retrospective study. Tumori 79: 214-218
15. Boyle F, Hancox D, Harvie R, Davey R, Friedlander M, McCaughan BC, Bell DR 1991 Detection of p-glycoprotein in nonsmall cell lung cancer and in nonmalignant lung tissue. Proc Annu Meet Am Assoc Cancer Res 32: 2175
16. Budworth J, Davies R, Malkhandi J, Gant TW, Ferry DR, Gescher A 1996 Comparison of staurosporine and four analogues: their effects on growth, rhodamine 123 retention, and binding to P-glycoprotein in multidrug-resistant MCF-7/Adr cells. Br J Cancer in press
17. Cattoretti G, Pileri S, Parravicini C, Becker MHG, Poggi S, Bifulco C et al 1993 Antigen unmasking on formalin-fixed, paraffin-embedded tissue sections. J Pathol 171: 83-98
18. Chan HS, Koren G, Thorner PS, Verjee Z, Haddad G, Giesbrecht E, Greenberg ML. Ling V, Gallie BL 1992 Reversal of multidrug resistance (MDR) in retinoblastoma (RB) by cyclosporin a (CsA). Proc Annu Meet Am Soc Clin Oncol 11: A1296
19. Chan HSL, Bradley G, Thorner P, Haddad G, Gallie BL, Ling V 1988 A sensitive method for the immunocytochemical detection of P-glycoprotein in multidrug-resistant human ovarian cancer cell lines. Lab Invest 59: 870-875
20. Chan HSL, Thorner PS, Haddad G, Ling V 1990 Immunohistochemical detection of P-glycoprotein: Prognostic correlation in soft tissue sarcoma of childhood. J Clin Oncol 8: 689-704
21. Cheng AL, Su IJ, Chen YC, Lee TC, Wang CH 1993 Expression of P-glycoprotein and glutathione-S-transferase in recurrent lymphomas: the possible role of Epstein-Barr virus, immunophenotypes, and other predisposing factors. J Clin Oncol 11: 109-115
22. Christen RD, McClay EF, Plaxe SC, Yen SS, Kim S, Kirmani S, Wilgus LL, Heath DD, Shalinsky DR, Freddo JL et al 1993 Phase I/pharmacokinetic study of high dose progesterone and doxorubicin. J Clin Oncol 11: 2417-2426
23. Cullen MH, Chetiyawardana AD, Joski R, Woodroffe CM 1988 Mitomycin, ifosfamide, and cisplatin in nonsmall cell lung cancer treatment good enough to compare. Br J Cancer 58: 359-361
24. Danova M, Giordano M, Erba E, Palmeri S, Candiloro V, Riccardi A, Ucci G, Mazzini G, D'Inalci M, Ascari E 1992 Flow cytometric analysis of multidrug resistance-associated antigen (P-glycoprotein) and DNA ploidy in human colon cancer. J Cancer Res Clin Oncol 118: 575-580
25. Darnton SJ, Jenner K, Steyn RS, Ferry DR, Matthews HR 1995 Lack of correlation of P-glycoprotein expression with response to MIC chemotherapy in oesophogeal cancer. J Clin Pathol 48: 1064-1066
26. Duran GE, Gosland MP, Ho AL, Sikic BI 1994 In vitro modulation of multidrug resistance (MDR) using human patient serum from KP-1: a phase I clinical trial of etoposide (VP-16) and SDZ PSC 833. Proc Annu Meet Am Assoc Cancer Res 35: A2093
27. Eck L, Pavich D, Fruehauf JP 1993 MDR-1 expression by human ovarian tumors is associated with Taxol resistance. Proc Annu Meet Am Assoc Cancer Res 34: A1388
28. Enzinger FM, Weiss SW 1988 Soft tissue tumours. In: Ferry DR, Russell MA, Cullen MH (eds) P-glycoprotein possesses a 1,4-dihydropyridine-selective drug acceptor site which is allosterically coupled to a vinca alkaloid-selective binding site. Biochem Biophys Res Commun 188: 440-445
29. 3H)-Taxol binds to a drug acceptor site which is allosterically coupled to the vinblastine-selective site of P-glycoprotein. Proc Am Ass Cancer Res 35: 348
30. Ferry DR, Russell MA, Kerr DJ, Correa ID, Prakash SR, Kerr DJ 1996 3H1GG918 (GF 120918) binds with positive co-opretivity to human P-glycoprotein with an nM dissociation constant. Proc Am Ass Cancer Res 37: 329
31. Ferry DR, Traunecker H, Kerr DJ 1996 Clinical trials of P-glycoprotein reversal in solid tumours. Eur J Cancer 32A: 1070-1081
32. Fidler U, Wilmanns C, Staroselsky A, Radinsky R, Dong Z, Fan D 1994 Modulation of tumor cell response to chemotherapy by the organ environment. Cancer Met Rev 13: 209-22
33. Flynn SD, Murren JR, Kirby WM, Honig J, Kan L, Kinder BK 1992 P-glycoprotein expression and multidrug resistance in adrenocortical carcinoma. Surgery 112: 981-986
34. Fojo AT, Ueda K, Slamon DJ, Poplack DG, Gottesman MM, Pastan I 1987 Expression of a multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci USA 84: 265-269
35. Gascoyne R, Tolcher A, Van Iderstin E 1993 The prognostic relevance of P-glycoprotein expression in malignant lymphomas. Proceedings of the General Motors Cancer Research Foundation Symposium, Toronto, Canada, A7
36. Georges E, Bradley G, Gariepy J, Ling V 1990 Detection of P-glycoprotein isoforms by gene-specific monoclonal antibodies. Proc Natl Acad Sci 87: 152-156
37. Goldie JH, Coldman AJ, Gudauskas GA 1982 Rationale for the use of alternating noncross-resislant chemotherapy. Cancer Treat Rep 66: 439-449
38. Goldstein LJ, Galski H, Fojo A, Willingham M, Lai SL, Gazdar A, Pirker R Green A, Crist W, Brodur G, Grant C, Leiber M, Cossmann J, Gottesmann MM, Pastan I 1989 Expression of multidrug resistance gene in human cancers. J Natl Cancer Inst 81: 116-124
39. Gottesman MM, Pastan P 1993 Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 62: 385-427
40. Guerci A, Merlin JL, Missoum N, Feldmann L, Marchal S, Witz F, Rose C, Guerci O 1995 Predictive value for treatment outcome in acute myeloid leukemia of cellular daunorubicin accumulation and P-glycoprotein expression simultaneously determined by flow cytometry. Blood 85: 2147-2153
41. Hamilton G, Raderer M, Cosentini KP, Hubsch P, Muller C, Thalhammer T, Zacher J, Scheithauer W, Wenzl E 1994 Microspectrofluorometric determination of Pgp-mediated Bodipy-verapamil efflux in tumor cell clusters from needle biopsy specimens. Proc Annu Meet Am Ass Cancer Res 35: A413
42. Huang CC, Wu MC, Xu GW, Li DZ, Cheng H, Tu ZX, Jiang HQ, Gu JR 1992 Overexpression of the mdr1 gene and p-glycoprotein in human hepatocellular carcinoma. J Natl Cancer Inst 84: 262-264
43. Hyafil F, Vergely C, Du VP, Grand PT 1993 In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res 53: 4595-4602
44. Itsuho M, Ishikawa T, Toda G, Tanaka M 1994 Immunohistochemical study of expression and cellular localization of the multidrug resistance gene product P-glycoprotein in primary liver carcinoma. Cancer 73: 298-303
45. Jones RD, Kerr DJ, Harnett AN et al 1990 A pilot study of quinidine and epirubicin in the treatment of advanced breast cancer. Br J Cancer 62: 133-135
46. Kartner N, Evernden-Porelle D, Bradley G, Ling V 1985 Detection of P-glycoprotein in multidrug-resistant cell lines by monoclonal antibodies. Nature 316: 20-23
47. Kelley DJ, Pavelic ZP, Gapany M, Stambrook P, Pavelic L, Gapany S, Gluckman JL 1993 Detection of P-glycoprotein in squamous cell carcinomas of the head and neck. Arch Otolaryngol Head Neck Surg 119: 411-414
48. Leier J, Jedlitschly G, Buchholz U, Keppler D 1994 Characterization of the ATP-dependent leukotriene C4 export carrier in mastocytoma cells. Eur J Biochem 220: 599-606
49. Linn SC, Giaccone G, Van DP, Blothuis WM, Van DVP, Van KC, Kuiper CM, Pinedo HM, Baak JP 1994 Prognostic relevance of P-glycoprotein expression in breast cancer. Proc Annu Meet Am Soc Clin Oncol 13: A212
50. Lum BL, Kaubisch S, Yahanda AM, Adler KM, Jew L, Ehsan M, Brophy NA, Halsey J, Gosland MP, Sikic BI 1992 Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporin in a phase I trial to modulate multidrug resistance. J Clin Oncol 10: 1635-1642
51. Lyttelton MPA, Hart S, Ganeshaguru K, Hoffbrand AV, Mehta AB 1994 Quantitation of multidrug-resistant MDR1 transcript in acute myeloid leukaemia by nonisotopic quantitative cDNA-polymerase chain reaction. Br J Haematol 86: 540-546
52. 3H)-vinblastine binding to P-glycoprotein of CCRF ADR 5000 cells. Eur J Pharmacol 288: 105-114
53. Marie JP, Brophy NA, Ehsan MN, Aihara Y, Mohamed NA, Cornbleet J, Chao NJ, Sikic BI 1992 Expression of multidrug resistance gene mdr1 mRNA in a subset of normal bone marrow cells. Br J Haematol 81: 145-152
54. Mason JT, O'Leary TJ 1991 Effects of formaldehyde fixation on protein secondary structure: a calorimetric and infrared spectroscopic investigation. J Histochem Cytochem 39: 225-229
55. Matsumoro J, Minami T, Sato T, Onodera T 1993 Hepatic arterial infusion chemotherapy combined with calcium antagonist for liver metastases. Gan To Kagaku Ryoho 20: 1538-1541
56. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL, Davidson M 1996 Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334: 1-6
57. Meyers MB, Rittman-Grauer L, O'Brien JP Safa AR 1989 Characterization of monoclonal antibodies recognizing a Mr 180,000 P-glycoprotein: differential expression of the Mr 180,000 and 170,000 P-glycoproteins in multidrug-resistant human cells. Cancer Res 49: 3147-3152
58. Miller TP, Grogan TM, Dalton WS, Spier CM, Scheper RJ, Salmon SE 1991 P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil. J Clin Oncol 9: 17-24
59. Motzer RJ, Lyn P, Fischer P, Lianes P, Ngo RL, Cordon-Cardo C, O'Brien JP 1995 Phase VII trial of dexverapamil plus vinblastine for patients with advanced renal cell carcinoma. J Clin Oncol 13: 1958-1965
60. Nishii K, Kita R, Miwa H, Ohno T, Yamagachi M, Oka K, Shirakawa S, Fulumoto M 1994 S 100-positive histiocytes in T-cell-dependent area in human lymphnodes express P-glycoprotein. Jpn J Cancer Res 85: 946-951
61. Noonan KE, Beck C, Holzmayer TA, Chin JE, Wunder JS, Andrulis IL, Gazdar AF, Willman CL, Griffith B, Von Hoff DD, Robininson IB 1990 Quantitative analysis of MDR1 (multidrug resistance) gene expression in human tumours by polymerase chain reaction. Proc Natl Acad Sci USA 87: 7160-7164
62. Patt YZ, Charnsangavej C, Yoffe B, Smith R, Lawrence D, Chuang V, Carrasco H, Roh M, Chase J, Fischer H et al 1994 Hepatic arterial infusion of floxuridine, leucovorin, doxorubicin, and cisplatin for hepatocellular carcinoma: effects of hepatitis B and C viral infection on drug toxicity and patient survival. J Clin Oncol 12: 1204-1211
63. Patt YZ, Mavligit GM 1991 Arterial chemotherapy in the management of colorectal cancer: an overview. Semin Oncol 18: 478-490
64. Pennock GD, Dalton WS, Roeske WR, Appleton CP, Mosely K, Plezia P, Miller TP, Salmon SE 1991 Systemic toxic effects associated with high-dose verapamil infusion and chemotherapy administration. J Natl Cancer Inst 83: 105-110
65. Petrylak DP, Scher HI, Reuter V, O'Brien JP, Cortion CC 1994 P-glycoprotein expression in primary and metastatic transitional cell carcinoma of the bladder. Ann Oncol 5: 835-840
66. Philip PA, Joel S, Monkman SC, Dolega-Ossowski E, Tonkin K, Carmichael J, Idle JR, Harris et al 1992 A phase I study of reversal of multidrug resistance (MDR) in vivo: nifedipine plus etoposide. Br J Cancer 65: 267-270
67. Pirker R, Wallner J, Gsur A, Gotzl M, Zochbauer S, Scheithauer W, Depisch D 1993 MDR1 gene expression in primary colorectal cancers. Br J Cancer 68: 691-694
68. Pourquier P, Coindre JM, Becouarn Y, Robert J 1993 Analysis of MDR1 (P-glycoprotein) gene expression in human gastric and colorectal adenocarcinomas. Clinical Biology of Cancers, 8th Symposium, April, 55
69. Pozza F, Bevilacqua P, Cazzavillan S, Meli S, Gasparini G 1993 P-glycoprotein expression (PGE) predicts chemoresistance (CR) in advanced breast cancer (ABC). Proc Annu Meet Am Soc Clin Oncol 12: A62
70. Pujol JL, Simony J, Gautier V, Marty AC, Pujol H, Michel FB 1993 Immunchistochemical study of P-glycoprotein distribution in lung cancer. Lung Cancer 10: 1-12
71. Rimsza L, Weinstein R, Rangel C, Grogan T 1994 Optimization of P-glycoprotein detection in formalin-fixed paraffin-embedded tissue using artigen retrieval methods. Anti-Cancer Drugs 5 (Supp 1): 11
72. Saltz L, Murphy B, Kemeny N, Beruno J, Tong W, Keefe D, Ty JY, Tao Y, Kelsen D, O'Brien JP 1994 A phase I trial of intrahepatic verapamil and doxorubicin. Regional therapy to overcome multidrug resistance. Cancer 74: 2757-2764
73. Scagliotti GV, Michelotto F, Leonardo E, Borasio P, Gubetta L, Pozzi E 1991 Immunohistochemical detection of glycoprotein p-170 and human epidermal growth factor receptor in resected nonsmall cell lung cancer. Proc Annu Meet Am Soc Clin Oncol 10: A876
74. Scheper RJ, Bulte JWM, Brakee JGP, Quak JJ, Van der Schoot E, Balm AJM, Meijer CJLM, Broxterman HJ, Kuiper CM, Lankelma J, Pinedo HM 1988 Monoclonal antibody JSB-1 detects a highly conserved epitope on the P-glycoprotein associated with multidrugresistance. Br J Cancer 42: 389-394
75. Scheulen ME, Nussler V, Kriegmair M, Lehmann M, Rathgeb F, Zech K, Wurst W, Kloth B, Schroder J, Wilmanns W et al 1994 Phase I study of i.v. dexniguldipine plus vinblastine. Proc Annu Meet Am Soc Clin Oncol 13: A419
76. Schrenk D, Gant TW, Preisegger KH, Silverman JA, Marino PA, Thorgeirsson SS 1993 Induction of multidrug resistance gene expression during cholestasis in rats and nonhuman primates. Hepatology 17: 854-860
77. Shi T, Wrin J, Reeder J, Lui D, Ring DB 1995 High-affinity monoclonal antibodies against P-glycoprotein. Clin Immunol Immunopathol 76: 44-51
78. Solary E, Velay I, Chauffert B, Bidan JM, Caillot D, Dumas M, Guy H 1991 Sufficient levels of quinine in the serum circumvent the multidrug resistance of the human leukemic cell line k562/adm. Cancer 68: 1714-1719
79. Sonneveld P, Durie BGM, Lothorst HM, Marie J-P, Solbu G, Zittoun R, Lowenberg B, Nooter K 1992 Modulation of multidrug-resistant myeloma by cyclosporin. Lancet 340: 255-258
80. Stein U, Wunderlich V, Haensch W, Schmidt PP 1993 Expression of the mdr1 gene in bone and soft tissue sarcomas of adult patients. Eur J Cancer 29: 1979-1981
81. Tabata M, Ohnoshi T, Ueoka H, Kiura K, Kimura I 1993 MDR1 gene expression and treatment outcome in small cell lung cancer: MDR1 gene expression as an independent prognostic factor. Acta Med Okayama 47: 243-248
82. Takahashi T, Takahashi T, Suzaki H, Hida T, Sekido Y, Ariyoshi Y, Ueda R 1991 The p53 gene is very frequently mutated in small-cell lung cancer with a distinct nucleotide substitution pattern. Oncogene 6: 1775-1778
83. Toth K, Vaughan MM, Slocum HK, Arredondo MA, Takita H, Baker RM, Rustum YM 1994 New immunohistochemical "sandwich" staining method for mdr1 P-glycoprotein detection with JSB-1 monoclonal antibody in formalin-fixed, paraffin-embedded human tissues. Am J Pathol 144: 227-236
84. Trump DL, Smith DC, Ellis PG, Rogers MP, Schold SC, Winer KP, Panella TJ, Jordan VC, Fine RL 1992 High-dose oral tamoxifen, a potential multidrug-resistance-reversal agent: Phase I trial in combination with vinblastine. J Natl Cancer Inst 84: 1811-1816
85. Twentyman PR, Rhodes T, Rayner S 1994 A comparison of rhodamine 123 accumulation and efflux in cells with P-glycoprotein-mediated and MRP-associated multidrug resistance phenotypes. Eur J Cancer 30a: 46-51
86. Van der Graaf WT, Buter J, De VEG, Willemse PH, Sleijfer DT, Mulder NH 1993 The effect of amiodarone on cytotoxicity of adriamycin and vinca-alkaloids: in vitro data and results of a phase II study. Proc Annu Meet Am Ass Cancer Res 34: A1267
87. Van Kalken CK, van der Hoven JM, de Jong J, Giaccone G, Schurhuis GJ, Maessen PA, Blokhuis WMD, van der Vigh WJF, Pinedo HM 1991 Bepredil in combination with anthracyclines to reverse anthracycline resistance in cancer patients. Eur J Cancer 27: 739-744
88. Venook P 1994 Treatment of hepatocellular carcinoma: too many options? J Clin Oncol 12: 1324-1334
89. Vergier B, Cany L, Bonnet F, Robert J, De MA, Coindre JM 1993 Expression of MDR1/P-glycoprotein in human sarcomas. Br J Cancer 68: 1221-1226
90. Verelle P, Meissonnier F, Fonk Y, Feillel V, Dionet C, Kwiatkowski F, Plagne R, Chassagne J 1991 Clinical relevance of immunohistochemical detection of multidrug resistance P-glycoprotein in breast carcinoma. J Natl Cancer Inst 83: 111-116
91. Volm M, Mattern J, Samsel B 1991 Overexpression of P-glycoprotein and gluthatione S-transferase-pi in resistant nonsmall cell lung carcinomas of smokers. Br J Cancer 64: 700-704
92. Watanabe M, Sugawara I, Yamashita T, Hasumi K, Masanuga A, Itoyama S 1993 P-glycoprotein expression and the degree of malignancy in anaplastic thyroid carcinoma. Proc Annu Meet Ass Cancer Res 34: A1373
93. Wilson WH, Bates SE, Fojo A, Bryant G, Zhan Z, Regis J, Wittes RE, Jaffe ES, Steinberg SM, Herdt J, Chabner BA 1995 Controlled trial of dexverapamil, a modulator of multidrug resistance in lymphomas refractory to EPOCH chemotherapy. J Clin Oncol 13: 1995-2004
94. Wishart GC, Plumb JA, Going JJ, McNichol AM, McArdle CS, Tsuruo T, Kaye SB 1990 P-glycoprotein expression in primary breast cancer detected by immunohistochemistry with two monoclonal antibodies. Br J Cancer 62: 758-761
95. Witherspoon SM, Emerson DL, Kerr BM, Lloyd TL, Dalton WS, Wissel PS 1996 Flow cytometry assay of modulation of P-glycoprotein function in whole blood by the multidrug resistance inhibitor GG918. Clin Cancer Res 2: 7-12
96. Woodhouse JR, Ferry DR 1994 The genetic basis of resistance to cancer chemotherapy: opening potential therapeutic avenues. Ann Int Med 27: 157-167